1. Home
  2. STRS vs IKT Comparison

STRS vs IKT Comparison

Compare STRS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stratus Properties Inc.

STRS

Stratus Properties Inc.

HOLD

Current Price

$28.31

Market Cap

230.9M

Sector

Real Estate

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.73

Market Cap

240.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STRS
IKT
Founded
1992
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
230.9M
240.1M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
STRS
IKT
Price
$28.31
$1.73
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
30.2K
672.2K
Earning Date
05-14-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
512.50
57.76
EPS
0.82
N/A
Revenue
$29,914,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$34.87
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.35
$1.33
52 Week High
$32.93
$2.26

Technical Indicators

Market Signals
Indicator
STRS
IKT
Relative Strength Index (RSI) 36.57 45.42
Support Level $28.22 $1.64
Resistance Level $31.37 $1.74
Average True Range (ATR) 0.82 0.10
MACD -0.07 -0.01
Stochastic Oscillator 15.49 38.24

Price Performance

Historical Comparison
STRS
IKT

About STRS Stratus Properties Inc.

Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the entitlement, development, management, leasing, and sale of multi-family and single-family residential and commercial real estate properties in the Austin, Texas area and other select markets in Texas. The company operates in two reportable segments: Real Estate Operations and Leasing Operations. Maximum revenue is generated from the Leasing Operations segment, which involves the leasing of commercial and residential properties developed by the company. The Real Estate Operations segment comprises properties under various stages of development: developed for sale, under development, and available for development.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: